Source: BioSig Technologies, Inc.
BioSig Technologies, Inc. (OTCQB: BSGM)
today announced the establishment of an advanced research program with
Dr. Samuel Asirvatham at Mayo Clinic in Rochester, Minnesota.
This
program has been designed to build upon the initial studies conducted
at Mayo Clinic in March, June and November 2015 through a tripling of
investment to fully characterize and develop novel features discovered
during this prior preclinical work. These features have the potential to
make a significant impact in the treatment of complex arrhythmias.
“We
are extremely pleased to continue our sponsored research activities
with Dr. Asirvatham and his colleagues at Mayo Clinic,” said Greg Cash,
President and CEO of BioSig Technologies. “The previous studies
confirmed the potential of PURE EP to improve the clarity of cardiac
signals while minimizing electrical noise in the cardiac
electrophysiology laboratory.”
About BioSig Technologies
BioSig
Technologies is a medical device company that is developing a
proprietary technology platform designed to improve the $4 billion EP
marketplace(1) (www.biosigtech.com).
Led by a proven management team and a veteran, independent Board of
Directors, Minneapolis-based BioSig Technologies is preparing to
commercialize its PURE EP System.
The PURE EP(TM)
System is a surface electrocardiogram and intracardiac multichannel
signal acquisition and analysis system designed to assist
electrophysiologists in making clinical decisions in real-time by
acquiring and displaying high-fidelity cardiac signal recordings and
providing clarity of data which may be used to guide the
electrophysiologists in identifying ablation targets - areas of tissue
to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts
forecast the global market for EP devices will grow at a 12.1 percent
compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion
by 2019(1), making it one of the fastest growing medical device
segments. Just in the US, the number of Atrial Fibrillation (AF) and
Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at
10.5 percent from 2012 to 2017(2).
BioSig intends
to seek FDA 510(k) clearance for the PURE EP System. The Company has
achieved proof of concept validation through UCLA labs, and has
performed pre-clinical studies at the Mayo Clinic in Minnesota. The
Company is collaborating with several of the nation's most prestigious
cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute,
UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
(2)
HRI 2013 "Global Opportunities in Medical Devices & Diagnostics"
report; triangulation of multiple sources; AF includes left atrial
tachycardia, left WPW, left atrial flutter.
No comments:
Post a Comment